Who Gets the Million Dollars When a Proof Has No Author?
The Navier-Stokes credit fight isn't a scandal — it's the first crack in a mathematical credit system built for a world that no longer exists.
The World Times
The Navier-Stokes credit fight isn't a scandal — it's the first crack in a mathematical credit system built for a world that no longer exists.
A post hoc analysis of the SELECT trial shows semaglutide shifts a dementia-risk biomarker. The gap between 'predicted' and 'actual' is the whole story.
OpenAI dropped ten math breakthroughs in a single paper with no named human authors. The real story isn't the AI — it's what happens to scientific credit when discovery becomes a product launch.
A preclinical HIV vaccine study hit the top of Hacker News this month. That says more about the collapse of trust in science communication than it does about the study itself.
Terence Tao's public ChatGPT session wasn't about verifying a counterexample; it was about establishing a new ritual of trust in an age of machine-generated knowledge.
Thursday's detection of an atmosphere on a distant rocky world is a triumph, but not for the reasons the headlines suggest. The instrument that found it is a rebuke to the privatize-everything gospel.
A new study on how modern design strains the brain is really a warning about the digital environments we inhabit for hours each day—and the business models that keep us there.
The ESO's call for a hard cap of 100,000 low-orbit satellites is scientifically rigorous and politically naive — and it dodges the question of who funds the alternative.
Scientists built a cell that grows and divides from scratch—an astonishing, historic, genuine achievement. But the way we talk about it says more about our hunger for revelation than about the science itself.
The outcry over political appointees reviewing grants misses a deeper rot — decades of academic science producing findings nobody asked for, on questions no voter would fund with their own money.
A University of Kansas pilot study found creatine slowed early Alzheimer's cognitive decline by roughly 30%. The real story isn't the science — it's what the silence from pharma tells us about which breakthroughs get funded.